KoreaTimes - Bio

The Korea Times

Entertainment & Arts

SCMP
Asia

The Korea Times

Entertainment & Arts

SCMP
Asia

The Korea Times

Business

Bio

Fri, June 9, 2023 | 10:46

Samsung chief vows to invest $5.2 bil. to create huge lead for bio business

Samsung chief vows to invest $5.2 bil. to create huge lead for bio business

Samsung Electronics Vice Chairman Lee Jae-yong has vowed to invest 7.5 trillion won ($5.2 billion) in the company's biotechnology firm by 2032 to achieve a huge lead with its competitors, Samsung Group said Tuesday. The Samsung chief attended the ceremony for the completion of Samsung Biologics' fourth drug manufacturing plant in Songdo, Incheon. The plant, which went into op...

Baek Byung-yeul | 2022-10-11 16:47

Samsung Biologics launches bispecific antibody platform S-DUAL

Samsung Biologics launches bispecific antibody platform S-DUAL

Samsung Biologics launched S-DUAL, a bispecific antibody platform developed with its own technology with an aim to improve its capability in the contract-based drug development business, the company said Thursday. Bispecific antibodies act on two factors simultaneously, not just one factor, which is more effective than a monospecific antibody that acts on only one factor.

Baek Byung-yeul | 2022-10-06 16:46

Korean biotech firms show off capabilities in Europe

Korean biotech firms show off capabilities in Europe

HLB, Celltrion, NeoImmuneTech and other Korean biotech companies confirmed their competitiveness in Europe as they showcased their new drug development capabilities at the European Society for Medical Oncology (ESMO) Congress, an annual medical oncology fair to share the latest developments in cancer research, they said Tuesday. This year's ESMO Congress was held in Paris for...

Baek Byung-yeul | 2022-09-13 16:46

HLB's liver cancer treatment shows longest overall survival

HLB's liver cancer treatment shows longest overall survival

Local biotech company HLB said its liver cancer treatment candidate Rivoceranib showed over 22 months of overall survival in its Phase 3 clinical trials, the longest in any liver cancer treatment, the company said, Thursday. The company said it plans to hold a meeting with the U.S. Food and Drug Administration (FDA) to apply for approval for new drugs, given the effectiveness...

Baek Byung-yeul | 2022-09-08 14:20

Celltrion receives approval to sell anticancer biosimilar Vegzelma in Europe

Celltrion receives approval to sell anticancer biosimilar Vegzelma in Europe

Korean biopharmaceutical firm Celltrion said Friday it has received an approval to sell its anticancer biosimilar Vegzelma in Europe.

2022-08-19 15:52

Samsung Biologics, C&T invest in US biotech firm Senda Biosciences

Samsung Biologics, C&T invest in US biotech firm Senda Biosciences

An investment fund created by Samsung Biologics and Samsung C&T invested $15 million into U.S.-based biotechnology company Senda Biosciences as part of their efforts to foster core technology required to develop next-generation biopharmaceuticals, Samsung Biologics said on Wednesday. Samsung Biologics said the Life Science Fund, jointly formed by itself and Samsung C&T, decid...

Baek Byung-yeul | 2022-08-17 16:16

Yoon promises to foster bio-health industry

Yoon promises to foster bio-health industry

President Yoon Suk-yeol vowed Wednesday to foster the bio-health industry into a key national strategic industry as he met with health experts at a medical research facility.

2022-07-27 14:13

Daesang to set up joint venture with China Sinopharm International

Daesang to set up joint venture with China Sinopharm International

Daesang Life Science, a Korean manufacturer of health functional foods, said Wednesday it has inked a letter of intent with China Sinopharm International to set up a joint venture in a bid to make forays into the Chinese market.

2022-07-27 14:13

Matica Bio aims to join global top 5 cell & gene therapy producers by 2030

Matica Bio aims to join global top 5 cell & gene therapy producers by 2030

Matica Biotechnology, a U.S. subsidiary of CHA Biotech, revealed its goal to join the global top five manufacturers of cell and gene therapy and generate sales of over 1 trillion won ($762.8 million) by 2030, its CEO said Thursday. “The global cell and gene therapy's CDMO (contract development and manufacturing organization) market is expected to grow by more than 20 percent ...

Baek Byung-yeul | 2022-07-21 16:10

Korean disease institute, Moderna agree to collaborate in SFTS mRNA vaccine development

Korean disease institute, Moderna agree to collaborate in SFTS mRNA vaccine development

Korea's state-run National Institute of Infectious Diseases (NIID) said Wednesday it has reached an agreement with Moderna, a U.S. biotech company, to cooperate in the development of a messenger RNA (mRNA) vaccine candidate for severe fever and thrombocytopenia syndrome (SFTS).

2022-07-20 13:18

1 2 3 4 5 6 7 8 9 10

Top 10 Stories

1	Dog meat traders condemn first lady, animal rights groups' push for ban

2	INTERVIEWSpaceX's Starlink in Kyiv is wake-up call for Seoul

3	Billy Graham Seoul Crusade celebrates 50th anniversary

4	Gov't to launch intensive crackdown against foreigners committing drug crimes

5	Home gardening boom inspires plant adoption, specialized care services for leafy companions

6	Korean businesses seek tougher punishments for industrial espionage

7	Yoon's labor reform drive sputters as umbrella union exits talks

8	Dollar remittance, foreign exchange rules to be eased

9	Yoon calls for all-out efforts to win chip war

10	Bookstore specializing in film is haven for readers and seaside lovers alike

DARKROOM